The page below is a sample from the LabCE course Tumor Markers. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Tumor Markers (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 97 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart


  1. Cancer Facts & Figures 2014. American Cancer Society web site. Available at: Accessed January 19, 2015.
  2. Chan DW, Booth RA, Diamandis EP. Tumor Markers. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. St. Louis, MO: Elsevier; 2006:745-795.
  3. Catalona WJ, Maggiore JA. PSA and Free-PSA Testing for Prostate Cancer is Still a Life Saver. Clinical Lab Products; February, 2005. Available at:". Accessed January 19, 2015.
  4. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < 4.0 ng per milliliter. N Engl J Med. 2004; 350:2239-2246.
  5. Stamey TA, Caldwell M, McNeal JE, Nolley R, et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urology. 2004;172:1297-1301.
  6. Lin K, Barton MB. Screening for Ovarian Cancer - Evidence Update for the U.S. Preventive Services Task Force Reaffirmation Recommendation Statement. AHRQ Publication No. 12-05165-EF-3 (United States Preventive Services Task Force); April 2012.
  7. American College of Obstetricians. Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: The Role of the Obstetrician–Gynecologist in the Early Detection of Epithelial Ovarian Cancer. Obstetrics & Gynecology. 2011; 117(3):742–746.
  8. Keshaviah A, Dellapasqua A, Rotmensz A, et al. for the International Breast Cancer Study Group. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Annals of Oncology. 2007; 18:701–708.
  9. Verring A, Clouth A, Ziolowski P, Oremek GM. Clinical usefulness of cancer markers in primary breast cancer. ISRN Pathology, 2011, Article ID 817618, 4 pages. doi:10.5402/2011/817618.
  10. Rack B, Schindbeck C, Jϋckstock J, et al. for the SUCCESS Study Group. Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment. Anticancer Res. May 2010; 30(5):1837-1841.
  11. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol.2007; 33(3):266–70.